Category: Liver Cancer

Worldwide info & news on Liver Cancer treatment and prevent tips help you to known more on Liver Cancer, iWeller shares Liver Cancer healthcare information with love.

Global demand for cancer surgery set to surge

Public health researchers, led by UNSW Sydney, have estimated the number of cancer cases requiring surgery globally each year, predicting the number will rise from 9.1 million to 13.8 million from 2018 to 2040 -- an increase of 52 per cent or 4.7 million cases. Their research shows...

Ivosidenib confers clinical benefit in advanced cholangiocarcinoma subset

January 25, 2021 3 min read Source/Disclosures Source: Zhu AX, et al. Abstract 266. Presented at: Gastrointestinal Cancers Symposium (virtual meeting); Jan. 15-17, 2021. Disclosures: Agios Pharmaceuticals funded this study. Zhu reports consultant/advisory roles with AstraZeneca, Bayer, Eisai, Exelixis, Gilead Sciences, Eli Lilly, Merck, Roche/Genentech and Sanofi/Aventis; and...

Pembrolizumab shows promising OS for previously untreated advanced HCC

First-line pembrolizumab induced durable antitumor activity and promising OS among patients with advanced hepatocellular carcinoma, according to data from the phase 2 KEYNOTE-224 study presented at Gastrointestinal Cancers Symposium.
Immunotherapy as monotherapy can offer “excellent benefit” for around 25% to 30% of patients in this setting, or it can be used in combinations to provide new treatment options for patients with hepatocellular carcinoma, according to Jean-Luc Van Laethem, MD, PhD, of the department of gastroenterology and digestive oncology at Hôpital Erasme -

Atezolizumab-bevacizumab combination provides ‘longest survival seen’ in advanced HCC

Atezolizumab plus bevacizumab conferred the longest OS seen in a phase 3 study for treatment-naive advanced hepatocellular carcinoma, according to updated results of the IMbrave150 study presented at Gastrointestinal Cancers Symposium.
Richard S. Finn, MD, professor of medicine in the department of medicine, division of hematology/oncology, at David Geffen School of Medicine at UCLA, reported median OS of 19.2 months with atezolizumab (Tecentriq, Genentech/Roche) and bevacizumab (Avastin, Genentech) compared with 13.4 months with sorafenib (Nexavar, Bayer).
“This is the longest survival

Validated risk score predicts post-transplant survival in HCC

Investigators developed a validated risk score to predict post-transplant survival for patients with hepatocellular carcinoma that will help prioritize patients based on predicted survival, according to study results."In the United States, all patients with liver cancer or HCC who...

The race is on for medical treatment of NASH

Nonalcoholic steatohepatitis is the second leading indication for liver transplantation in the United States but there are currently no FDA-approved treatments available.Rohit Loomba, MD, MHSc, director of the NAFLD Research Center and director of hepatology, professor of medicine at...

Alcohol-related liver disease increases risk for cancer

Patients with alcohol-related liver disease who survive for at least 1 year after diagnosis are at increased risk for cancer, according to study results.Hannes Hagström, of the division of hepatology at Karolinska University Hospital in Sweden, and colleagues wrote...
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language

Site Categories

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.